|
 |
BusulfanThis page contains recent news articles, when available, and an overview of Busulfan but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Busulfan (when available) Busulfan is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death. For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Mechanism Of Action: Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. News Articles on Busulfan MILs emerge as imporant tools in drug delivery and theranostics - Dec 15, 2009 ...on a porous iron (III)-based metal–organic framework for delivering several drugs: busulfan, azidothymidine triphosphate, doxorubicine, and cidofovir. ... Ethiopian Review Home administration of high-dose oral busulfan in patients undergoing... - Feb 26, 2007 Correspondence: Dr RH Matthews, Pharmacy, Northside Hospital, 5670 Peachtree Dunwoody Road, Suite 1020, Atlanta, GA 30342, USA. ... Nature.com … intensity conditioning using intravenous busulfan, fludarabine and... - Dec 5, 2005 The conditioning regimen consisted of iv busulfan from day -9 to -6, ... Busulfan dose was determined based on a test dose (0.5 mg/kg) done on day -13, ... Nature.com Possible role of high-dose busulfan in second reciprocal transplant … - Feb 21, 2005 Rana et al 1 published a report of a girl affected by a stage IV B-cell non-Hodgkin (Burkitt) lymphoma who relapsed 8 months after the initial diagnosis and ... Nature.com Busulfan (Systemic). - Aug 1, 2006 Busulfan ( byoo-SUL-fan) belongs to the group of medicines known as alkylating agents. It is used to treat some kinds of cancer of the blood. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Busulfan (Systemic). - Jul 28, 2005 Busulfan ( byoo-SUL-fan) belongs to the group of medicines known as alkylating agents. It is used to treat some kinds of cancer of the blood. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com How It Works - Nov 26, 2008 Research shows that interferon is better than busulfan or hydroxyurea in treating CML. But interferon also causes more side effects. 1 ... WebMD Busulfan Loading into Poly(Alkyl Cyanoacrylate) Nanoparticles - Oct 10, 2006 Busulfan, which belongs to a family of drugs known as alkylating agents, is used to treat hematological malignancies, including chronic myelogenous leukemia ... AZoNano.com … York State Health Department Approves Busulfan Testing by Memorial... - Dec 12, 2007 The State of New York Department of Health has approved the testing protocol submitted by the Department of Clinical Labs at Memorial Sloan- Kettering ... Genetic Engineering News - Genetic Engineering News (press release) Arup Will Develop Antibody-Based Busulfan Blood Monitoring Test - Oct 30, 2006 Arup Laboratories will develop a specialized test for measuring serum concentrations of the cancer chemotherapeutic agent busulfan (Busulfex®, ... Genetic Engineering News - Genetic Engineering News (press release) MyFox Wausau | Myleran - Uses, Side Effects, Interactions, Warnings, ... - Jun 20, 2008 Busulfan belongs to the group of cancer-fighting medicines known as antineoplastics, ... Busulfan is used to treat leukemia (cancer of white blood cells). ... MyFox Wausau … Biomedical Sign Agreement for Busulfan Analyte Specific Reagents. - Oct 30, 2006 ARUP Laboratories and Saladax Biomedical Sign Agreement for Busulfan Analyte Specific Reagents. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Stem Cell Transplantation; Standard IV busulfan dose in children may... - Feb 8, 2005 2005 FEB 8 - (NewsRx.com & NewsRx.net) -- A standard IV busulfan dose in children does not always fall within the defined AUC reference range. ... Pay-Per-View - Science Letter - Factiva, from Dow Jones … reduced-intensity conditioning therapy with fludarabine and busulfa... - Jan 8, 2007 Fludarabine is commonly used in combination with busulfan as part of ... So far, no data are available on busulfan–fludarabine drug interactions in ... Nature.com … Anderson Cancer Center, Houston; Standard IV busulfan dose in... - Feb 9, 2005 2005 FEB 9 - (NewsRx.com & NewsRx.net) -- A standard IV busulfan dose in children does not always fall within the defined AUC reference range. ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Stem Cell Transplantation; Standard IV busulfan dose in children may... - Feb 12, 2005 2005 FEB 12 - (NewsRx.com & NewsRx.net) -- A standard IV busulfan dose in children does not always fall within the defined AUC reference range. ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Nanoparticle encapsulation improves bioavailability of leukemia drug - Oct 9, 2006 Busulfan, which belongs to a family of drugs known as alkylating agents, ... The two chief challenges the researchers faced were that busulfan is chemically ... News-Medical.net Safe administration of oral BU twice daily during conditioning for... - Dec 17, 2007 Hassan M, Ehrsson H. Urinary metabolites of busulfan in the rat. ... Plasma concentration monitoring of busulfan: does it improve clinical outcome? ... Nature.com Nanoparticle Encapsulation Improves Bioavailability of Leukemia Drug - Oct 16, 2006 Busulfan, which belongs to a family of drugs known as alkylating agents, ... The two chief challenges the researchers faced were that busulfan is chemically ... nanotechwire.com Risk factors for hepatic veno-occlusive disease: a retrospective... - Jun 30, 2008 Busulfan disposition was only studied in 20 of 116 patients and no correlation was ... Busulfan was the first drug administered in the conditioning regimen. ... Nature.com … /SCF signaling loss increases male germ cell depletion following... - Jan 2, 2005 ..."Three and four weeks after busulfan treatment," continued Choi, "RAD51 and FasL expression decreased to nearly undetectable levels, indicating that meiotic ... Pay-Per-View - Medical Devices & Surgical Technology... - Factiva, from Dow Jones Autologous bone marrow transplantation for children with AML in first... - Jun 11, 2007 Conditioning consisted of 4 days of busulfan (4 mg/kg/day) given orally in four ... It is possible to use intravenous busulfan or optimize the dose of oral ... Nature.com Trente-deux mesures pour lutter contre le cancer - Mar 10, 2008 ...le Rituximab ou le Busulfan IV. Une procédure d'annonce du diagnostic sera mise au point pour faire en sorte que ce moment particulièrement difficile ... 7sur7 Otsuka Pharmaceutical Co Ltd acquires PDL Biopharma Inc-IV Busulfex … - Mar 10, 2008 Life…a definitive agreement under which Otsuka will acquire from PDL the rights to IV Busulfex (busulfan). In July ####, IV Busulfex was approved for use ... Pay-Per-View - deals - Alacra Store Allogeneic hematopoietic cell transplantation (HCT) in Hurler's... - Nov 19, 2007 1) received a previous bone marrow allograft with a conditioning regimen of busulfan, cyclophosphamide and rabbit ATG 288 days prior to the HCT reported ... Nature.com Efficacy of neodymium:YAG laser therapy for gastric antral vascular … - Nov 7, 2005 All patients had received oral busulfan and four had sinusoidal obstruction syndrome. ... Oral busulfan appears to be necessary for the development of GAVE ... Nature.com In patients with Chediak–Higashi syndrome undergoing allogeneic SCT, ... - Jul 16, 2007 In the study by Eapen et al., 1 the combination of busulfan and ... In the same way, we used busulfan, cyclophosphamide and etoposide at our institution on ... Nature.com Risk stratification for survival and leukemic transformation in... - Dec 14, 2006 Conversely, cytogenetic findings were normal in one patient who received prior therapy with a combination of hydroxyurea, busulfan and uracil mustard. ... Nature.com Vitamin K deficiency in children pre-bone marrow transplantation - Nov 14, 2005 The other three patients received phenytoin as busulfan-induced seizure prophylaxis. Five of 26 patients (19%) were conditioned with the Bu/Cy protocol and ... Nature.com Fludarabine/iv BU conditioning regimen: myeloablative, reduced... - Feb 11, 2008 Once-daily intravenous busulfan given with fludarabine as conditioning for ... Conditioning with fludarabine and targeted busulfan for transplantation of ... Nature.com Stem Cell Transplantation; Researchers report details of new studies... - Jun 24, 2005 Study 2: Intravenous busulfan-fludarabine is effective with low toxicity in acute ... Median busulfan clearance was 109 mL/minute/m2 and median daily ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Press Release: Otsuka Pharmaceutical and PDL BioPharma Close Sale … - Mar 10, 2008 IV Busulfex (busulfan) is indicated for use in combination with ... WARNING: Busulfex (busulfan) Injection is a potent cytotoxic drug that causes profound ... Pay-Per-View - PR Newswire - HighBeam Research Myelodysplastic syndrome after autologous peripheral blood stem cell ... - Aug 6, 2007 ...or busulfan 1 mg/kg po 12 doses on days -6 to -4 and melphalan 200 g/m 2 iv on day -3 (busulfan and melphalan (BU/MEL)), cyclophosphamide 1 g/m 2 iv on ... Nature.com Early engraftment kinetics of two units cord blood transplantation - Jun 19, 2006 Patients 5 and 7 received fludarabine (180 mg/m 2 ) and iv busulfan (12.8 mg/kg). Patient 8 received fludarabine (240 mg/m 2 ), iv busulfan (12.8 mg/kg) and ... Nature.com Help Consumatori - Leggi news - May 19, 2005 In particolare, il Busulfan è indicato nel condizionamento prima del trapianto di cellule progenitrici emopoietiche negli adulti; la Bivaluridina per il ... Help Consumatori Autologous SCT with a dose-reduced BU and CY regimen in older … - Sep 15, 2008 Dose modification protocol using intravenous busulfan (Busulfex) and ... Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and ... Nature.com Successful cord blood transplantation in a premature and dysmature … - Jan 29, 2007 In view of the extremely low weight, prematurity and the uncertainty of busulfan kinetics in this infant, the risk of a full myeloablative conditioning ... Nature.com Reduced intensity conditioning allows for up-front allogeneic … - Feb 16, 2006 In the first four patients a DMSO-based iv busulfan instead of melphalan was ... The first 4 patients received busulfan 3.3 mg/kg iv for two days (day -6, ... Nature.com Autologous stem cell transplantation for high-risk Ewing's sarcoma... - Nov 7, 2005 Phenytoin was administered during busulfan therapy (starting 24 h before the first dose and continuing for 24 h after the last dose). ... Nature.com Allogeneic stem cell transplantation in Fanconi anemia patients … - Nov 5, 2007 Bitan et al., 18 on the other hand, reported more encouraging results with the use of fludarabine plus cytoxan and/or busulfan in addition to ATG in the ... Nature.com Stem Cell Transplantation; Reports advance knowledge in stem cell … - Feb 22, 2005 Study 3: Intravenous busulfan-fludarabine is effective with low toxicity in acute ... Median busulfan clearance was 109 mL/minute/m2 and median daily ... Pay-Per-View - Cancer Weekly - Factiva, from Dow Jones Preservation of ovarian function by ovarian shielding when undergoing... - Jan 30, 2006 However, spontaneous recovery of ovarian function is rarely seen after a combination of busulfan and cyclophosphamide, another major conditioning regimen ... Nature.com Six cases of permanent alopecia after various conditioning regimens … - Sep 10, 2007 Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G. Busulfan concentration in relation to ... Busulfan bioavailability. Blood 1994; 84: 2144–2150. ... Nature.com Stem Cell Transplantation; Reports advance knowledge in stem cell … - Feb 25, 2005 Study 3: Intravenous busulfan-fludarabine is effective with low toxicity in acute ... Median busulfan clearance was 109 mL/minute/m2 and median daily ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Successful outcome of allo-SCT in high-risk pediatric AML using … - Jun 16, 2008 Ferry C, Socie G. Busulfan-cyclophosphamide versus total body ... Role of busulfan and total body irradiation on growth of prepubertal children receiving ... Nature.com Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in... - Aug 1, 2006 In vitro data suggest that this effect may extend to busulfan, but not to chloroethylating agents such as cyclophosphamide and melphalan. ... Nature.com Reduced-intensity conditioning lowers treatment-related mortality of ... - Apr 14, 2005 TBI more than 10 Gy hyperfractionated; busulfan 16 mg/kg; busulfan 12 mg/kg plus melphalan 140 mg/m 2 ; and busulfan 10 mg/kg plus thiotepa 20 mg/kg. ... Nature.com Unrelated donor hematopoietic cell transplantation for hemophagocytic... - May 5, 2008 We show here that the regimen of busulfan, cyclophosphamide, etoposide with ... Despite the apparent activity for busulfan, cyclophosphamide, etoposide with ... Nature.com New method of administering anti-cancer drug may be more effective, … - May 18, 2005 The drug busulfan is used in leukemia patients to kill cancerous cells before ... Then researchers administered busulfan by the novel method - patients ... eurekalert.org Clinical effect of imatinib added to intensive combination chemotherap... - Apr 23, 2005 Conditioning regimens were as follows: BuCy (busulfan 3.2 mg/kg/day iv or 4 mg/kg orally for 4 days, then cyclophosphamide 60 mg/kg/day iv for 2 days) in 14 ... Nature.com Reduced intensity conditioning in unrelated donor transplantation for... - Jun 25, 2007 Busulfan, cyclophosphamide and melphalan as preparative regimen to allogeneic stem cell ... Reduced intensity conditioning using intravenous busulfan, ... Nature.com Novel way of administering an anti-cancer drug to bone-marrow … - May 20, 2005 The drug busulfan is used in leukemia patients to kill cancerous cells before ... Then researchers administered busulfan by the novel method - patients ... News-Medical.net Successful Hematopoietic Stem Cell Transplantation for Niemann-Pick … - Oct 19, 2005 Her busulfan dose yielded a steady- state concentration of only 277 ng/mL ... The busulfan dose was increased, and a repeat steady-state concentration was ... RedOrbit New method of administering anti-cancer drug may be more effective, … - May 23, 2005 The drug busulfan is used in leukemia patients to kill cancerous cells before ... Then researchers administered busulfan by the novel method - patients ... i-newswire.com Stem cell transplantation in children with infantile osteopetrosis is... - Sep 4, 2006 Whereas busulfan (either oral or iv) was used in all patients, cyclophosphamide, ... Thiotepa, busulfan and cyclophosphamide as a preparative regimen for ... Nature.com The early referral for reduced-intensity stem cell transplantation in... - Oct 10, 2005 6, 7 In 2002, we published a report on 21 patients with CML who were given an RIST, 6 using the 'Mexican approach', 4, 9 which employs fludarabine, busulfan ... Nature.com Increasing mixed chimerism and the risk of graft loss in children … - Apr 7, 2008 The busulfan, fludarabine and rATG conditioning regimen was replaced with a busulfan, ... Reduced intensity conditioning using intravenous busulfan, ... Nature.com Cytogenetic response to prior treatment with interferon- is predictive... - Feb 2, 2006 An evidence-based analysis of the effect of busulfan, hydroxyurea, ... Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic ... Nature.com Immune Ablation and Autologous Stem Cell Transplantation for … - Oct 22, 2007 The immunoablation was comprised of: busulfan 9.6 mg/kg, cyclophosphamide 200 mg/kg, and rabbit ATG 5 mg/kg, with the ASCT carried out with G-CSF 5 ... DG News New drug to beat smoking approved. - Jan 16, 2007 Busulfan (Busilvex) is accepted as part of treatment before ... Busulfan is given by an injection which is better than the current method by mouth. ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com Prior treatment with the tyrosine kinase inhibitors dasatinib and... - Jul 3, 2008 The typical reduced-intensity conditioning was the combination of fludarabine (total dose150 mg/m 2 ) and reduced-dose busulfan (total dose 6.4 mg/kg). ... Nature.com Outcome of alveolar hemorrhage in hematopoietic stem cell transplant ... - May 7, 2007 In the multivariate reduced model, renal dysfunction, thrombocytopenia and use of busulfan+fludarabine or melphalan+fludarabine for preconditioning were ... Nature.com A pilot study of low-dose recombinant interleukin-2 for acute … - Jul 21, 2008 ...sibling (n=6) allo-HSCT received myeloablative therapy that included a combination of cytosine arabinoside (Ara-C; 2 g/m 2 1 day), busulfan (12 mg/kg), ... Nature.com Reduced-Intensity Transplantation Feasible in Chronic Myeloid Leukemia - Nov 25, 2005 ..."I tend to favor the fludarabine/busulfan regimens, but the evidence is weak." "There remains a role for allogeneic transplant in CML despite the efficacy ... Cancerpage.com Interferon- after autologous stem cell transplantation in pediatric... - Apr 18, 2006 Individual patients received the following regimen: busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg); thiotepa (750 mg/m 2 ), busulfan (480 mg/m 2 ) and ... Nature.com The effect of administration order of BU and CY on toxicity in … - Dec 15, 2008 Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell ... Once-daily intravenous busulfan and fludarabine: clinical and ... Nature.com Gender aspects in chronic myeloid leukemia: long-term results from … - Apr 14, 2005 Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. ... Nature.com Cell fusion contributes to pericyte formation after stroke - Aug 21, 2008 Briefly, busulfan (20 mg/mL in PBS containing 1% dimethyl sulfoxide; Sigma, Madrid, Spain, ... The newborn busulfan-conditioned R26R mice were transplanted, ... Nature.com Unrelated bone marrow transplantation using a reduced intensity- … - Mar 13, 2006 A nonmyeloablative conditioning regimen with busulfan alone may thus be able to reverse the disease phenotype in canine leukocyte adhesion deficiency (CLAD) ... Nature.com Allogeneic hemopoietic stem cell transplants for patients with... - Feb 5, 2007 Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term ... Nature.com Biochemical indices for the assessment of nutritional status during … - Jul 16, 2007 Patients with acute and chronic myeloid leukemia, sarcoma granulocyticum and myelodysplastic syndromes received busulfan and cyclophosphamide as a ... Nature.com Progress in Genetic Therapy for Severe Combined Immunodeficiency … - Apr 1, 2006 Prolonged neutropenia in both patients appeared related to abnormal busulfan metabolism kinetics. All but two patients remain off chronic pegylated (PEG) ... Nature.com Non-myeloablative stem cell transplantation in patients with relapsed... - Jul 9, 2007 Patients received oral busulfan 4 mg/kg/day for 2 days; iv cyclophosphamide 350 mg/m 2 /day for 3 days; and iv fludarabine 30 mg/m 2 /day for 3 days. ... Nature.com HLA-C mismatch is associated with inferior survival after unrelated... - Mar 13, 2006 Patients were conditioned with busulfan (0.8 mg/kg/day iv 4 days) and fludarabine (30 mg/m 2 /day iv 4 days). Graft-versus-host disease prophylaxis included ... Nature.com Does hematopoietic stem cell transplantation improve patient outcome... - Mar 1, 2005 Before transplantation, all patients received a standardized preparatory regimen consisting of busulfan, cyclophosphamide and melphalan. ... Nature.com The role of reduced intensity conditioning allogeneic stem cell … - Apr 21, 2005 17 The RIC regimen administered before allo-SCT included fludarabine, busulfan and antithymocyte globulin. Detailed transplant procedures were described ... Nature.com Neonatal Lupus and IUGR Following Alpha-Interferon Therapy during … - Jun 2, 2005 Treatment modalities include busulfan, anagrelide, platletpheresis and ... Busulfan is a known teratogen and anagrelide is known to cross placenta and cause ... Nature.com Dendritic cells in autologous hematopoietic stem cell transplantation... - Oct 10, 2005 In all, 52 (98%) of the patients received a combination preparative regimen consisting of busulfan, cyclophosphamide and etoposide, while one patient ... Nature.com Successful treatment of autoimmune hemolytic anemia with rituximab in... - Mar 7, 2005 Conditioning consisted of busulfan (8 mg/kg), cyclophosphamide (200 mg/kg) and rabbit antithymocyte globulin (30 mg/kg). The graft was TCD by means of ... Nature.com Effect of prior rituximab on high-dose therapy and autologous stem... - Sep 17, 2007 All 106 patients had at least one prior chemotherapy regimen, and all were treated with the same preparative regimen, which consisted of busulfan, ... Nature.com Prophylactic infusion of donor granulocyte colony stimulating factor ... - Dec 3, 2005 ...which consisted of TBI with 7.7 Gy and Cy 1.8/m 2 /day 2 days or the modified busulfan-cyclophosphamide regimen (mBuCy), which consisted Ara-C 2g/m 2 ... Nature.com Allogeneic stem cell transplantation from unrelated donor for class 3... - Oct 31, 2005 The conditioning regimen was composed of cyclophosphamide (50 mg/kg once daily iv on days -4, -3, -2 and -1), busulfan (2 mg/kg/day on days -8, -7, ... Nature.com Association of MBL gene polymorphisms with major bacterial infection... - Jan 27, 2005 ...cyclophosphamide), acute lymphoid leukemia (busulfan, etoposide, cytarabine), and multiple myeloma (total body irradiation (TBI)+melphalan (L-PAM)). ... Nature.com Katie receives life-saving bone marrow transplant - Sep 27, 2007 The first is busulfan, meant to kill Katie's bone marrow to make room for her brother's. The Trebings know busulfan is one of the chemo drugs that can cause ... Newsday Chronic kidney disease in long-term survivors of hematopoietic cell … - Sep 25, 2006 Myeloablative regimens were typically cyclophosphamide-based (with either TBI or busulfan) for allogeneic transplants; many autologous graft recipients ... Nature.com Allogeneic blood SCT for children with Hurler's syndrome: results... - Oct 13, 2008 Nguyen L, Fuller D, Lennon S, Leger F, Puozzo CIV busulfan in ... Fried W, Kedo A, Barone J. Effects of cyclophosphamide and of busulfan on spleen ... Nature.com Height growth during adolescence and final height after haematopoietic... - Nov 17, 2008 Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with ... Nature.com Allogeneic hematopoietic stem cell transplantation provides sustained... - Mar 3, 2005 In this analysis, there was no difference in the incidence of relapse or survival among patients treated with busulfan-based regimens and TBI-containing ... Nature.com Allogeneic hematopoietic stem-cell transplantation in patients with... - Mar 10, 2005 Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell ... Once-daily intravenous busulfan and fludarabine: clinical and ... Nature.com High-dose chemotherapy with autologous stem cell transplantation as... - Apr 11, 2006 High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. ... Nature.com Article: Taking a Chance With a Clinical Trial. - Kiplinger's... - Oct 1, 2006 Article: Sparta Pharmaceuticals Inc. announces initiation of busulfan ... ... Sparta's new intravenous form of Spartaject(TM) busulfan ... ... Pay-Per-View - Kiplinger's Retirement Report - HighBeam Research Article: Clinical Trial Volunteers Mostly Indifferent - But Not Blind... - Apr 4, 2008 Article: Sparta Pharmaceuticals Inc. announces initiation of busulfan ... ... Sparta's new intravenous form of Spartaject(TM) busulfan ... ... Pay-Per-View - AScribe Law News Service - HighBeam Research Gemtuzumab therapy for isolated extramedullary AML relapse following ... - Feb 27, 2007 4, 8 This patient did not receive purged stem cells, and his conditioning regimen and prior chemotherapy did not contain busulfan—an agent that has been ... Nature.com Bone marrow transplantation for cartilage-hair-hypoplasia - Oct 16, 2006 Response to conditioning with busulfan and cyclophosphamide as well as prophylaxis with corticosteroids and cyclosporine A was similar in CHH patients when ... Nature.com Comparable non-relapse mortality and survival after HLA-identical... - Nov 5, 2007 Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted ... Nature.com Umbilical Cord Blood for Older Patients - Dec 11, 2007 The reduced-intensity conditioning regimen consisted of 200 cGY total-body irradiation and cyclophosphamide and fludarabine in 69 patients, busulfan and ... Medscape Protein Design to acquire ESP Pharma. - Jan 1, 2005 IV Busulfex (busulfan) Injection. Indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic ... Free with registration - BIOTECH Patent News - AccessMyLibrary.com First Demonstration of "Apparently Fully Curative" Gene Therapy - Dec 11, 2006 Busulfan was administered at 2 mg/kg per day on days 3 and 2 prior to the transplant and resulted in a transient myelosuppression in most patients, ... Medscape Summary and The Case - Mar 20, 2007 She was treated with chemotherapy including sibling bone marrow transplant with busulfan/cyclophosphamide conditioning. A three-generation family history ... Medscape Allogeneic Hematopoietic Cell Transplantation for Refractory Myastheni... - Dec 21, 2008 Results The patient underwent a reduced-toxicity conditioning with intravenous busulfan, fludarabine, and alemtuzumab, followed by a peripheral blood stem ... Archives of Neurology Recent Studies Produce Promising Results in Effectively Treating... - Dec 11, 2005 Busulfan is a type of chemotherapy that interferes with the growth of cancer cells, slowing their growth and spread in the body. ... Free with registration - PR Newswire - AccessMyLibrary.com Brand Names/Synonyms: Busulfan is also known by the following brand names and/or synonyms2041 C. B.; AN 33501; Busulfan; Busulfex; Busulphan; Busulphane; Butanedioldimethanesulfonate; Buzulfan; C.B. 2041; CB 2041; Citosulfan; G.T. 41; GT 2041; GT 41; Leucosulfan; Mablin; Mielevcin; Mielosan; Mielucin; Milecitan; Mileran; Misulban; Mitosan; Mitostan; Myeleukon; Myeloleukon; Myelosan; Myelosanum, Busulphan; Mylecytan; Myleran; Myleran Tablets; NCI-C01592; NSC 750; NSC-750; Nsc-750sulphabutin; Sulfabutin; Sulphabutin; Tetramethylene Dimethane Sulfonate; Tetramethylenester Kyseliny Methansulfonove; X 149 Drug Category: Busulfan is categorized under the following by the FDA: Antineoplastic Agents; Immunosuppressive Agents; Alkylating Agents; ATC:L01AB01 Dosage Forms: SOLUTION; TABLET Absorption: Completely absorbed from the gastrointestinal tract. Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 1,4-bis(methylsulfonyloxy)butane |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
